SangKon Oh;Jacques F. Banchereau;Christine Morel Coquery;HyeMee Joo;Maria Virginia Pascual
发明人:
SangKon Oh,Maria Virginia Pascual,Jacques F. Banchereau,Christine Morel Coquery,HyeMee Joo,Oh, Sangkon,Pascual, Maria Virginia,Banchereau, Jacques F.,Coquery, Christine Morel,Joo, Hyemee
申请号：
US13489851
公开号：
US20120308578A1
申请日:
2012.06.06
申请国别(地区):
US
年份:
2012
代理人:
摘要：
The present invention provides a method for treating a patient at risk for or diagnosed systemic lupus erythematosus (SLE) by determining the overall expression of syndecan-1 in one or more cells of a patient suspected of having SLE； and predicting the efficacy of a therapy with a pharmaceutical agent for treating the patient, wherein a decrease in the overall expression of syndecan-1 in the patient cells when compared to the expression of syndecan-1 in normal cells indicates a predisposition to responsiveness to anti-neoplastic agent therapy, wherein the therapy comprises administering an effective amount of the pharmaceutical agent to the patient.
